Stuart A. Aaronson
| Stuart A. Aaronson, M.D. | |
|---|---|
 |
|
| Born |
February 28, 1942 Mount Clemens, Michigan |
| Alma mater | UC Berkeley, UC SF |
| Occupation | biologist |
| Employer | The Mount Sinai Hospital |
| Known for | Cancer research |
| Title | Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Founding Chair Emeritus of Oncological Sciences |
Stuart A. Aaronson, M.D., is an American author and internationally recognized cancer biologist. He has authored more than 500 publications and holds over 50 patents, and was the Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences at The Mount Sinai Hospital in New York City until March 2013, when he assumed the title of Founding Chair Emeritus of the Department of Oncological Sciences. The current Chairman of Oncological Sciences is Ramon E. Parsons.
Aaronson graduated summa cum laude from the University of California, Berkeley, in 1962, with a degree in chemistry. He earned his M.D. from the University of California, San Francisco Medical Center in 1966, and completed a fellowship at the University of Cambridge in England and an internship in medicine at Moffitt Hospital in San Francisco.
In 1967, Aaronson joined the National Institutes of Health as a Senior Staff Fellow. He headed the Molecular Biology Section of the Viral Carcinogenesis Branch from 1970 until 1977, after which he became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, until 1993, when he was named Chairman of Oncological Sciences at The Mount Sinai Hospital.
Aaronson's early research established the transformation-competent but replication-defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes. His investigations of the v-sis oncogene established the first normal function of an oncogene and its role in growth factor signaling. His discovery of erbB2 as a v-erbB-related gene amplified in a human breast carcinoma and the demonstration of its transforming properties paved the way for targeted therapies directed against its product, and his successful isolation of KGF (FGF7), a growth factor present in the epithelialization-phase of wound healing, led to Amgen's successful phase III clinical trial and FDA approval of KGF for treatment of mucositis. Current research includes investigations into the mechanisms by which tumor suppressor genes induce permanent growth arrest/senescence, the signaling pathways involved, and investigations of the autocrine and paracrine acting growth factors PDGF, KGF, , and Wnt ligands.
...
Wikipedia